The pharmaceutical company announced an investment of R$650 million. Photo: Igor Baggio
The year 2020 showed an atypical scenario and full of challenges due to Covid-19. Although the effects of the health crisis remain, Prati-Donaduzzi pharmaceutical industry, located in Toledo, Paraná, grows at an accelerated pace and maintains its strategic plan for 2021.
The pharmaceutical company announced an investment of R$650 million, which was confirmed last year with the arrival of three Fette compressors. Such compressors are the most modern ones in the world, a complete and automated line of packaging of Italian origin and preparation equipment with European technology that together are part of the first stage of the project to increase production capacity and modernize the current facilities.
“During the pandemic, our main concern was with the health and well-being of our employees. They were essential in ensuring that Brazilians did not lack medicines. Even with the health crisis, we have not reduced our investments and we continued with our growth projection”, says the CEO of Prati-Donaduzzi, Eder Fernando Maffissoni.
Also in 2020, the company started the construction of a new high-tech manufacturing facility at its headquarters, which, in full operation, will place Prati-Donaduzzi even more prominently on the market, due to the high production capacity that will reach 17 billion doses per year.
The steps for the future are being built in the present and the industry will start operations in the coming weeks from a Distribution Center (DC), located on the margins of PR 182 highway, KM 320 in Toledo. The site will have more than 14 thousand square meters and will have the capacity to house 17,500 pallet positions.
Being considered a benchmark in the production of medicines in Brazil, Prati-Donaduzzi also expanded its product portfolio last year and wrote a new chapter in its trajectory, mainly in the history of Brazilian medicine, with the authorization of the Brazilian Health Regulatory Agency (Anvisa) for the production of the first Cannabis-based product, Cannabidiol Prati-Donaduzzi.
This launch allowed a leap forward in a new area of activity for the company, Medical Prescription. With the launch of new branded products, more than 28,600 medical visits were carried out in person and online. In addition, several meetings of continuing medical education were held, which together add up to the participation of more than 2,000 professionals from different specialties.
“Our planning is very solid and will be well executed by our team. We intend to reach many more physicians in 2021. We will have a historic year for the Medical Prescription area and also for Prati”, emphasizes the Medical Prescription director, Edilson Bianqui.
Currently, the industry has more than 400 presentations available to the population. In 2021, the portfolio is expected to renew through new launches, mainly branded drugs, which are aimed at the Central Nervous System (CNS) and indicated to treat diseases such as epilepsy, Parkinson's, Alzheimer's, anxiety, depression, neuropathic pain, schizophrenia, autism, bipolarity and insomnia.
This portfolio growth is the result of high investments in the Research, Development & Innovation (RD&I) area. Recently, the industry has developed a national high technology for the production of Alzheimer's drugs.
“One of the great pillars of Prati-Donaduzzi is innovation. The constant investments in RD&I show the pharmaceutical company's commitment to providing health and well-being”, says Prati-Donaduzzi CEO.
The pharmaceutical company is even considered one of the most innovative companies in the South of Brazil and also in the country. The obtained results show the structured advances in RD&I, which are factors that guaranteed the company this result.
Being considered a benchmark in the production of medicines in Brazil, Prati-Donaduzzi also expanded its product portfolio. Photo: Prati-Donaduzzi Press
The purple box is synonymous with quality and high technology, which is proven by customers who trust Prati-Donaduzzi medicines. In 2020, the company advanced in sales and allowed more people to have access to treatments. The advances are exemplified by sales, where the industry presented an increase of 26%.
The respect for the consumer was proven by the recognition of the Best Companies in Customer Satisfaction Institute (MESC), which ranked the pharmaceutical industry among the top 100 in the country in 2020. This excellence is also demonstrated by the evaluation of customers on the Reclame Aqui portal, with a score of 9.1, being considered by the channel as “Great” in service.